In Thursday’s Wall Street session, Chemours Company (NYSE:CC) shares traded at $11.47, down -3.37% from the previous session.
CC stock price is now 1.81% away from the 50-day moving average and -30.18% away from the 200-day moving average. The market capitalization of the company currently stands at $1.72B.
With the price target maintained at $19, Mizuho recently Upgraded its rating from Neutral to Outperform for Chemours Company (NYSE: CC). On January 28, 2025, Truist recently initiated its ‘Buy’ rating on the stock quoting a target price of $27, while ‘UBS’ rates the stock as ‘Buy’
In other news, Gumpel Damian, insider bought 13,400 shares of the company’s stock on Jun 02 ’25. The stock was bought for $123,548 at an average price of $9.22. Upon completion of the transaction, the insider now directly owns 123,879 shares in the company, valued at $1.42 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 03 ’25, Gumpel Damian bought 7,822 shares of the business’s stock. A total of $77,828 was incurred on buying the stock at an average price of $9.95. This leaves the insider owning 131,701 shares of the company worth $1.51 million. A total of 0.75% of the company’s stock is owned by insiders.
During the past 12 months, Chemours Company has had a low of $9.13 and a high of $25.80. As of last week, the company has a debt-to-equity ratio of 7.57, a current ratio of 1.75, and a quick ratio of 0.83.
The net profit margin was 0.53% and return on equity was 4.66% for CC. For the current quarter, analysts expect CC to generate $1.56B in revenue.
